46
Views
4
CrossRef citations to date
0
Altmetric
CaseReport Article

First report of Cryptococcus laurentii meningitis and a fatal case of Cryptococcus albidus cryptococcaemia in AIDS patients

, , , , , & show all
Pages 335-339 | Accepted 20 May 1998, Published online: 09 Jul 2009
 

Abstract

We report the first case of Cryptococcus laurentii meningitis and a rare case of Cryptococcus albidus cryptococcaemia in AIDS patients. Both infections were treated with amphotericin B and flucytosine. The C laurentii meningitis was controlled after 2 weeks of treatment with no evidence of infection 20 months later. The patient with C albidus cryptococcaemia, despite the amphotericin B/flucytosine combination therapy, died on the 14th day of treatment. The minimum inhibitory concentrations (MICs) for C laurentii, as determined by Etest on RPMI 1640 agar, were 0·25 μg ml-1of amphotericin B, 1·25 μg ml-1 flucytosine, 4 μg ml -1 fluconazole, 0·50 μg ml-1 itraconazole and 1·0μg ml-1 of ketoconazole. The MIC of amphotericin B for C. albidus was 0·5 μg ml-1, flucytosine 1·25 μg ml-1, fluzonazole 4 μg ml-1, itraconazole 0·5 μg ml-1 and ketonazole 0·25 μg ml-1. The agreement of the amphotericin B MIC values obtained in antibiotic medium 3 by the broth microdilution method, with those obtained on casitone medium by Etest, was within a two-dilution range for both isolates. C laurentii may cause meningitis and may also involve the lungs in AIDS patients.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.